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We tested the eﬀect of electroacupuncture (EA) on lower urinary tract symptoms (LUTS) in benign prostatic hyperplasia (BPH)
patients. A total of 42BPH patients with LUTS were randomly assigned to either the EA group (EG), received 2Hz EA for 20min
twice/week for a total of twelve treatments, or a sham EA group (CG), received sham EA. The increase of voiding volume, average
ﬂowrate, andmaximalﬂow ratein theEG were 32.2±104.4mL,1.2±1.6mL/sec,and2.3±3.7mL/sec,respectively, from baseline
value (before EA) using the measurement of an uroﬂowmetry. These increases were greater than −37.9 ± 120.4, −0.22 ± 2.7, and
−0.3 ± 4.3, respectively, in the CG (P = .038, .026, and .030, resp.). The changes of prostate special antigen and international
prostatic symptom score were not signiﬁcantly diﬀerent between two groups (P = .573, .175, resp.), suggesting the clinical
improvement of 2Hz EA was quite limited to the LUTS of patients with BPH.
1.Introduction
Benign prostate hyperplasia (BPH) is a common condition
in men over 50 years of age. BPH and prostate size increase
continuously with age [1]. Sommer et al. (1990) found
that the prevalence and the severity of voiding symptoms
including obstructive and irritative symptoms increased in
menbetween50and60yearsofage,suggestingarelationship
to BPH [2]. The prevalence BPH is 20.2% in men 40–64
years of age and 42.8% in men 65–79 years of age in the
community in central Scotland [3]. The symptoms of BPH
includesobstructive symptoms ofweak urinary stream force,
hesitancy, intermittent, terminal dribbling and incomplete
bladder emptying, and irritative symptoms of frequency,
nocturia, and urgency. These symptoms may aﬀect quality
of life [3–5]. The symptoms of BPH increase with age in
Japanese men, as they do in men in the United States [6].
It has been observed that prostate size does not correspond
to the severity of obstruction and other symptoms [7].
The international prostate symptom score (IPSS) scoring
system has been developed by the American Urological
Association [8]. This scores system, from 0 to 35, covers
mild, moderate, and severe lower urinary symptoms, and
includes seven questions relating to voiding and ﬁlling
symptoms in the scoring system. The IPSS is a sensible and
reliable system clinically [8] and has been used widely in
the clinic for the evaluation of the severity of lower urinary
tract symptoms (LUTS) in patients with BPH [5, 9, 10].
Uroﬂowmetry is one of the simplest urodynamic methods
and is noninvasive and, thus, plays a critical role in the
assessment of obstructive LUTS in patients with BPH [11].
Uroﬂowmetry together with symptomatology constitute a
reliable method for preoperative evaluation in patients with
BPH [12]. That the maximum ﬂow rate (Qmax), average
ﬂow rate (Qave), and volume of voided urine are lower in
patients with BPH and that the total ﬂow time and time2 Evidence-Based Complementary and Alternative Medicine
to start voiding are longer than those of healthy men have
beenreportedinastudyusing uroﬂowmetry [13].Therefore,
uroﬂowmetry may be used as an index to evaluate the
severity of symptoms in patients with BPH. Prostate speciﬁc
antigen (PSA) is an important tumor marker of prostate
cancer and has been widely used in the early diagnosis and
management of patients with BPH or with prostate cancer
[14, 15].
Although nonselective alpha blockers such as Doxaosin
or Prazosin and selective alpha blocker such as Tamsulosin
can mitigate LUTS in patients with BPH, these drugs
may cause side eﬀect of postural hypotension fatigue and
dizziness, [5, 16]. Finasteride as an alpha reductase inhibitor
may decrease the volume of BPH and also may decrease the
rate of hematuria and prostate cancer, but it may result in
sexual dysfunction [5, 17]. Acupuncture has been used to
treat LUTS for thousands of years. Acupuncture treatment
achieves greater reduction in frequency and urgency and
results in greater increase in functional bladder capacity and
greater improvement in the score of an incontinence impact
questionnaire than does placebo treatment in women with
overactive bladder [18]. Acupuncture also may reduce the
National Institutes of Health chronic prostatitis symptom
index (NIH-CPSI) in total score and pain score, as well as
urinary and quality-of-life scores in patients with chronic
prostatitis/chronic pelvic pain syndrome [19]. Johnstone et
al. (2003) reported that acupuncture cannot relieve LUTS
and PSA in BPHpatients [20]. In contrast,others havefound
that electroacupuncture (EA) at Zhongji (CV3) may sig-
niﬁcantly improve Qmax, frequency of nocturia, and urine
steam[21],andEAatZhonjiandHuiyin(CV1)mayimprove
Qmax and postvoided residual urine [22]. Therefore, the
eﬀect of EA on the LUTS in BPH patients needed further
study. We designed a single-blinded, randomized pilot study,
a n du s e du r o ﬂ o w m e t r y ,I P S S ,a n dP S Aa si n d i c e s .
2.MaterialandMethods
2.1.Subjects. Atotalof91men with BPH,who suﬀered from
LUTS including incomplete empting, frequency, intermit-
tency, urgency, straining, and nocturia were enrolled from
December 2008 to December 2009 at Chi Mei Medical
Center(Tainan,Taiwan).Forty-sevenpatientswereexcluded,
and two patients refused to participate in the trial. Forty-
two men with BPH participated in the present study. The
study protocol was approved by the institutional review
board of Chi Mei Medical Center (IRB no. 09712-001).
The procedures of the trial were in accord with the ethical
principles dictated in the Declaration of Helsinki,a n dt h e
informed consent form was signed by each participant after
detailed explanation of the trial purpose and procedure.
BPH was conﬁrmed by a urology specialist using the
transrectal sonography survey, and PSA also was measured
for exclusion of prostate cancer. The inclusion criteria
included(1)age>40,(2)BPHintheabsenceofanyprevious
anti-BPH treatment such as alpha blocker medications, or
surgical operation, (3) IPSS > 8, and (4) Qmax < 15mL/sec.
The exclusion criteria were (1) ﬁnding that the lower urinary
symptoms were due to interstitial cystitis, prostate cancer,
urinary stone, or urinary tract infection, (2) any medical
condition such as congestive heart failure, hypertensive
patients treated with beta blockers, arrhythmia with or
without cardiac pacemaker, chronic pulmonary obstructive
disease, and hepatic failure, and (3) inability of the potential
participant to comply with the schedule of the trial.
2.2. Randomization and Blinding. Forty-two patients were
randomized by lottery to the EA group (EG), which received
EA, or to the control group (CG), which received sham EA.
Each group had 21 subjects (Figure 1).
2.3. Study Design and Sample Size. The present study was a
pilot study ofa single-blind randomized controlled trial. The
samplesizewascalculatedaccordingtoKoseogluetal.(2006)
[23]and Lohet al. (2009)[9]. We predicted a dropoutrate of
15%; therefore, twenty-one subjects would be suﬃcient.
2.4. EA. EA was performed by a Chinese medical doctor
with more than 4 years of acupuncture experience. In the
EG, the subjects were treated with stainless steel acupuncture
disposable needles (2 cun in length, gauge #30, Yu Kuang,
Taiwan) inserted into the Zhongji (CV3) and Guanyuan
(CV4) and bilateral Zusanli (ST36) and Sanyinjiao (SP6)
acupoints. The acupuncture needles were twisted manually
3–5 times to obtain qi (in which the acupuncturist has the
sensation of ﬁsh biting on bait; the subject experiences a
hot and tightness feeling). The Zhongji, Guanyuan, Zusanli,
and Sanyijiao needles were connected to electroacupuncture
apparatus (HC-0501, Hung-Tai Co., Taiwan).
Three pairs of EA were designed as Zhongji and
Guanyuan, ipsilateral Zusanli and Sanyinjiao. These acu-
points were chosen according to the selection of local points
and according to meridian theory of Traditional Chinese
Medicine. Zhongji and Guanyuan acupoints are located in
the midline of the low abdomen, and 4cun and 3cun,
respectively, inferior to the umbilicus, and belong to the
conception vessel near the urinary bladder. Both acupoints
may treat urinary disease including frequency, urgency, and
dribbling [24]. The Zusanli acupoint is located 3cun below
the knee, belongs to the stomach meridian, and the acupoint
may treat diﬃcult urination [25]. The Sanyijiao acupoint is
located 3cun above the medial malleolus and belongs to the
spleen meridian, and the acupoint may treat uroschesis and
stranguria [26].
The frequency of EA was 2Hz. The intensity of electrical
stimulation was adjusted to obtain visible twitching of
muscle about 2–2.5mA. The subject did not feel pain
or discomfort. The duration of electrical stimulation was
20min and was performed two times per week for 6
consecutive weeks for a total of twelve sessions. In the CG,
the methods were identical to those in the EG, except that
theacupunctureneedles were inserted into thesubcutaneous
tissue to a depth of 2mm, the location was 1cm lateral
to the above-mentioned acupoints, respectively, without
manual twisting or any electrical stimulation. The checklist
of consolidated standards of reporting trials (CONSORT)Evidence-Based Complementary and Alternative Medicine 3
(1) 91 patients benign prostate hyperplasia with low urinary
tract symptoms were enrolled
(2) 47 patients were excluded
(3) 2 patients refused into trial
(4) 42 patients correspond to inclusion criteria
Randomized
Electroacupuncture group Control group
2Hz electroacupuncture
(1) GV3-GV4 pair
(2) ST36-SP6 pair (left)
(3) ST36-SP6 pair (right)
(2) ST36-SP6 pair (left)
(3) ST36-SP6 pair (right)
Sham electroacupuncture
(1) GV3-GV4 pair
(1) Twice/week consecutive 6weeks total of 12times, each time was 20min in duration
(2) PSA and uroﬂowmetry were measured before and at ﬁnishing 12times electroacupuncture
(3) IPSS was measured before, at ﬁnishing 6times, and at ﬁnishing 12times electroacupuncture
(1) 18 patients ﬁnished trial
(2) 2 patients withdrew due to work reason
(3) 1 patient withdrew due to feel no eﬀect
(1) 19 patients ﬁnished trial
(2) 1 patient withdrew due to time reason
(3) 1 patient withdrew due to knee operation
Statistical analysis
(n = 21) (n = 21)
Figure 1: Flowchart.
was completed [27] and complete details of the intervention
are presented in Table 1 in conformance to the standards
forreporting interventionsincontrolledtrial ofacupuncture
[28].
2.5. Outcome Measures. The primary outcome measures
were the diﬀerences of Qmax, average ﬂow rate (Qave), total
ﬂow time, and void volume from baseline (before EA) to
after completion of twelve rounds of EA (F2). Those indices
were measured using uroﬂowmetry (UROCOMPACT 6000,
LABORIE, ENCORE).
The secondary outcome measures were the change of
serum PSA concentration measured baseline and at F2,
and the diﬀerences of IPSS includs incomplete empting,
intermittency, weak stream, straining, frequency, urgency,
and nocturia from baseline to after completion of six rounds
of EA (F1), and from baseline to F2.
2.6. Statistical Analysis. The data are presented as mean
± standard deviation (SD) and are analyzed by SPSS for
Windows, version 17.0 (SPSS Inc., Illinois, USA). Mann-
WhitneyUtestwasusedtoassessthediﬀerencesbetweentwo
groups.Thesigniﬁcance levelwassetatα = 0.05.P<. 05was
considered to indicate a statistically signiﬁcant diﬀerence.
3.Results
3.1. Basic Characteristics. Forty-two BPH patients with
LUTS participated in this trial. Three patients withdrew in
the EG, two patients withdrew because of work, and one
patientbecausehefeltnoeﬀect.Twopatientswithdrewinthe
CG, one patient withdrew because of the time commitment
and one patient because of a knee operation. Therefore,
a total of 37 subjects completed the trial (Figure 1). No
signiﬁcant diﬀerences were found between the EG and CG
in basic characteristics including age, prostate volume, IPSS,
voidingvolume,totalﬂowtime,Qave,Qmax,andserumPSA
levels (Table 2).
Three patients in the EG developed subcutaneous ecchy-
mosisinthelowerabdominalregion.These ecchymoseswere4 Evidence-Based Complementary and Alternative Medicine
Table 1: Standards for reporting interventions in controlled trials of acupuncture (STRICTA).
Acupuncture rationale (1) According to the selection of local points, and meridian theory of traditional Chinese medicine
(2) Classic acupoints: CV3 (Zhongji), CV4 (Guanyuan), ST36 (Zusanli),SP6 (Sanyinjiao)
Needling detail
(1) Single or bilateral acupoints
(2) Six needles inserted
(3) Depth of insertion: muscle layer in electroacupuncture (EA) group, and subcutaneous tissue in sham
EA group
(4) Responses elicited: obtain qi and visible twitching of muscle in EA group, and no responses elicited in
sham EA group
(5) Needle stimulation:manual to obtain qi following by electrical stimulation in EA group, and no
manual or any electrical stimulationin sham EA group
(6) Needle retention time: 20min
(7) Needle type: stainless steel needles, 2cun in length, gauge#30, Yu Huang, Taiwan
Treatment regimen (1) Twice per week for 6 weeks
Cointerventions (1) None: no herbs, moxibustion, cupping, massage, exercise, advice dietary or lifestyle modiﬁcation
Practitioner background (1) License-certiﬁcated Chinese medical doctor with more than four years of acupuncture experience
Control intervention (1) Nil
Table 2: Basic character.
EG (n = 18) CG (n = 19) P value
Age (years) 63.2 ±10.05 9 .8 ± 9.0 .399
Prostate volume (mL) 36.0 ±11.83 8 .4 ± 17 .910
IPSS 22.8 ± 4.42 1 .4 ± 3.1 .276
Voiding volume (mL) 190.7 ±109.4 254.6 ±122.6 .051
Total ﬂow time (sec) 51.8 ±22.15 5 .5 ±24.6 .706
Average ﬂow rate (mL/sec) 4.0 ±1.94 .9 ±1.8 .131
Maximal ﬂow rate (mL/sec) 9.7 ±3.21 1 .2 ± 2.5 .128
PSA (ng/mL) 2.5 ±2.23 .4 ±3.5 .589
Datapresentas mean ± standarddeviation;EG:electroacupuncture group; CG:shamelectroacupuncture group; IPSS:International ProstateSymptomscore;
PSA: prostate-speciﬁc antigen.
all less than 3cmin diameter and disappeared spontaneously
without any treatment. No one withdrew from the trial for
this reason.
3.2. Eﬀect of EA on Voiding Symptoms in BPH Patients. The
increases in void volume, Qave, and Qmax from baseline
to F2 were greater in the EG than in the CG (P = .038,
.026, .030,resp.;Table 2),whiletheincreaseoftotalﬂowtime
wasnotsigniﬁcantlydiﬀerentbetweenEGandCG(P = .607;
Table 3).
3.3. Eﬀect of EA on LUTS and PSA in BPH Patients. The
changes of IPSS from baseline to F1, and from baseline to
F2 were not signiﬁcantly diﬀerent between EG and CG (P =
.314, .175, resp., Table 4).
The changes of serum PSA levels from baseline to F2 was
not signiﬁcantly diﬀerent between EG and CG (P = .573;
Table 4).
The changes of subscore of IPSS including incomplete
empting, frequency, intermittency, urgency, weak stream,
straining, andnocturiafrombaselinetoF1andfrombaseline
to F2 were not signiﬁcantly diﬀerent between EG and CG
(Table 5).
4.Discussion
The results in the present study indicated that increases in
voidingvolume,Qave,andQmaxweregreaterintheEGthan
in the CG in BPH patients with LUTS, whereas total ﬂow
time, and IPSS and subscore of IPSS in the EG was similar
to that in the CG. These results suggested that the clinical
improvement of 2HzEA was quite limited to the LUTS of
patients with BPH. The 2HzEA may enhance the release of
enkephalin,β-endorphin,andendomorphinrelease,whereas
100HzEA increase the release of dynorphin. A combination
of 2Hz and 100HzEA may induce simultaneous release of
all four opioid peptides produce maximal therapeutic eﬀect
[29, 30]. Therefore, how to increase therapeutic eﬀect of EA,
further study is need. Basic characteristics of age, prostate
size, voiding volume, total ﬂow time, Qave, and Qmax were
not signiﬁcantly diﬀerent between two groups.
Uroﬂowmetry may be used for preoperative routine
assessment of BPH patients [12]. The Qmax may predict the
degree of obstruction in patients with BPH because there is
a negative correlation between Qmax and prostate volume
[31]. The Qmax is a reliable and objective measurement to
evaluate the symptoms of BPH patients, because there is
negative correlation between Qmax and the InternationalEvidence-Based Complementary and Alternative Medicine 5
Table 3: Eﬀect of electroacupuncture on voiding symptoms in patients with benign prostate hyperplasia.
EG (n = 18) CG (n = 19) P value
Voiding volume (mL)
Baseline 190.7 ±109.4 254.6 ±122.6 .051
6 weeks 230.1 ±107.9 223.4 ±127.8 .749
Baseline-6 weeks 32.2 ±104.4 −37.9 ± 120.4 .038∗
Total ﬂow time (sec)
Baseline 51.8 ±22.15 5 .5 ±24.6 .706
6 weeks 42.5 ±22.15 2 .7 ±31.5 .380
Baseline-6 weeks −10.5 ± 30.6 −3.69 ± 26.4 .607
Average ﬂow rate (mL/sec)
Baseline 4.0 ±1.94 .9 ±1.8 .131
6 weeks 5.3 ±2.24 .7 ±2.3 .309
Baseline-6 weeks 1.2 ±1.6 −0.22 ±2.7 .026∗
Maximal ﬂow rate (mL/sec)
Before 9.7 ±3.21 1 .2 ±2.5 .128
6 weeks 11.8 ±4.71 0 .9 ±4.2 .792
Baseline-6weeks 2.3 ±3.7 −0.3 ± 4.3 .030∗
Data present as mean ± standard deviation; EG: electrooacupuncture group; CG: sham electroacupuncture group; Baseline: before electracupuncture; 6
weeks: at ﬁnishing 6 consecutive weeks total twelve times electroacupuncture; Baseline-6 weeks: the diﬀerence between baseline and at 6 weeks; ∗P<. 05 EG
versus CG.
Table 4: Eﬀect of electroacupuncture on lower urinary symptoms and prostate speciﬁc antigen in patients with benign prostate hyperplasia.
EG (n = 18) CG (n = 19) P value
IPSS
Baseline 22.8 ±4.42 1 .4 ±3.1 .276
3 weeks 19.5 ±4.31 8 .7 ±4.0 .640
6 weeks 18.0 ±3.81 8 .2 ±4.5 .932
Baseline-3weeks −3.2 ±2.4 −2.6 ± 3.2 .314
Baseline-6weeks −4.4 ±2.6 −3.05 ±3.8 .175
PSA (ng/mL)
Baseline 2.5 ±2.23 .4 ±3.5 .589
6 weeks 2.4 ±2.13 .4 ±3.7 .573
Baseline-6 weeks −0.12 ±0.54 −0.03 ± 1.08 .573
Data present as mean ± standard deviation; EG:electroacupuncture group; CG: shamelectroacupuncture group; IPSS: international prostate symptom score;
PSA: prostate-speciﬁc antigen; Baseline: before electroacupuncture; 3 weeks: at ﬁnishing 3 consecutive weeks total six times electroacupuncture; 6 weeks: at
ﬁnishing 6 consecutive weeks total twelve times electroacupuncture; Baseline-3 weeks: the diﬀerence between baseline and at 3 weeks; Baseline-6 weeks: the
diﬀerence between baseline and at 6 weeks.
Continence Society-BPH (ICS-BPH) symptom score [32].
The ICS-BPH symptom score is obtained by using an
ICSmale questionnaire, and has a high level of psychometric
validity and reliability [33]. Our results also indicated that
IPSSanditssubscoreandPSAwere notsigniﬁcantlydiﬀerent
between the EG and the CG. The IPSS is a sensible and
reliable method to assess LUTS including emptying symp-
toms: incomplete emptying, intermittency, weak stream, and
straining and storage symptoms: frequency, urgency, and
nocturia in BPH patients [8], whereas subscores of IPSS
consist of the emptying symptoms score and the storage
symptoms score [34].
One report ﬁnds that with the IPSS, it is diﬃcult to
predict the severity of the symptoms in China [35]. Other
reports demonstrate that the correlation is poor between
total IPSS and bladder outlet obstruction [36, 37]. Because
of bladder outlet obstruction is related to the dysfunction of
detrusor [38]. The prostate size is a very weak determinant
factor of the severity of symptoms and bladder outlet
obstruction, because the bladder outlet obstruction of BPH
included both static and dynamic factors that have a rela-
tionship to the tension of the prostate smooth muscle [39].
The LUTS are induced by BPH due to obstruction causing
detrusor dysfunction, resulting in neural alteration of the
bladder and prostate [40]. PSA is important tumor marker
of prostate cancer that is used for early detection in patients
with BPH and in the management of patients with prostate
cancer [15]. EA may partly improve voiding function of
patients with BPH. Acupuncture is about twice as eﬀective
as sham acupuncture in the treatment of patients with pro-
statitis/chronic pelvis pain [41]. Acupuncture may work via
a somatoautonomic reﬂex to reduce or increase gastroduo-
denal motility. In rats, acupuncture in the abdomen, which
excites sympathetic nerves through a spinal reﬂex, reduces6 Evidence-Based Complementary and Alternative Medicine
Table 5: Eﬀect of electroacupuncture on subscore of IPSS in patients with benign prostate hyperplasia.
EA (n = 18) CG (n = 19) P value
Incomplete emptying
Baseline 3.4 ± 1.23 .4 ±1.2 .766
3 weeks 2.9 ± 1.33 .0 ±0.9 .799
6 week 2.8 ± 1.33 .1 ±0.9 .443
ΔBaseline-3 weeks 0.56 ± 1.04 0.37 ±0.60 .94
￿Baseline-6 weeks 0.67 ± 1.03 0.32 ±0.67 .461
Frequency
Baseline 3.3 ±1.13 .4 ±1.1 .834
3 weeks 2.9 ± 0.92 .9 ±1.2 .940
6 weeks 2.7 ± 1.32 .7 ±1.2 .940
ΔBaseline-3 weeks 0.44 ± 0.62 0.47 ±0.77 .730
￿Baseline-6 weeks 0.67 ± 0.59 0.62 ±1.01 .298
Intermittency
Baseline 3.1 ± 1.03 .0 ±1.2 .675
3 weeks 2.7 ± 1.02 .9 ±1.2 .499
6 weeks 2.7 ± 1.02 .8 ±1.2 .851
ΔBaseline-3 weeks 0.39 ± 0.50 0.05 ±0.62 .159
￿Baseline-6 weeks 0.35 ± 0.49 0.21 ±0.63 .594
Urgency
Baseline 2.8 ± 1.52 .7 ±1.1 .938
3 weeks 2.5 ± 1.22 .3 ±1.1 .707
6 weeks 2.3 ± 1.12 .4 ±1.2 .753
ΔBaseline-3 weeks 0.33 ± 0.97 0.47 ±0.90 .707
￿Baseline-6 weeks 0.56 ± 1.04 0.32 ±1.0 .685
Weak stream
Baseline 3.4 ± 1.03 .2 ±1.0 .490
3 weeks 3.1 ± 1.02 .8 ±0.8 .518
6 weeks 3.1 ± 0.92 .7 ±0.7 .245
ΔBaseline-3 weeks 0.28 ± 0.46 0.32 ±0.58 1.000
￿Baseline-6 weeks 0.33 ± 0.59 0.47 ±0.70 .775
Straining
baseline 3.3 ± 1.03 .2 ±0.7 .705
3 weeks 2.8 ± 1.02 .9 ±0.7 .753
6 weeks 2.7 ± 0.92 .8 ±0.7 .707
ΔBaseline-3 weeks 0.44 ± 0.62 0.26 ±0.65 .443
￿Baseline-6 weeks 0.56 ± 0.70 0.37 ±0.83 .518
Nocturia
Baseline 2.6 ± 1.02 .6 ±1.2 .961
3 weeks 2.1 ± 0.92 .0 ±1.2 .893
6 weeks 1.6 ± 0.72 .0 ±1.0 .358
ΔBaseline-3 weeks 0.50 ± 0.62 0.32 ±0.7 .988
￿Baseline-6 weeks 1.0 ± 0.84 0.58 ±0.9 .271
Data present as mean ± standard deviation; EG: electroacupuncture group; CG: sham electroacupuncture group; Baseline: before electroacupuncture; 3
weeks: at ﬁnishing 3 consecutive weeks total six times electroacupuncture; 6 weeks: at ﬁnishing 6 consecutive weeks total twelve times electroacupuncture; Δ:
diﬀerence between baseline and at 3 weeks;
￿:d i ﬀerence between baseline and at 6 weeks.
gastricmotility.Acupunctureinthehindlimbs,whichexcites
the vagus nerve via a supraspinal reﬂex, increases gastric
motility [42]. Acupuncture or electrical stimulation may
increase the production of endorphins and analgesic eﬀects
to generate a neuromodulation to decrease the high tone of
thepelvicﬂoorwhichisinducedbybladderdysfunction[43].
The reﬂexotherapy of EA can improve sensory urgency in
BPH patients with transurethral resection [44]. To sum up,
EA increase the voiding volume, Qave, and Qmax of BPH
patients with LUTS, possibly through many pathways. The
neuromodulation of the bladder induced by acupuncture
appears to play a critical role.Evidence-Based Complementary and Alternative Medicine 7
Although the results of the present study indicated
that 2HzEA of Zhongji, Guanyuan, ipsilateral Zusanli,
and Sanyinjiao might increase the voiding volume, Qave,
and Qmax of BPH patients with LUTS, the study still is
unclear that these acupoints are essential or stimulation of
others acupoints also eﬀective or not. Therefore, further
the examination of some other acupoints eﬀect is needed.
Acupuncture apply to CV1 (Huiyin), Guanyuan, Sanyinjiao
and SP9 (Yinlingquan) 2 weekly sessions for 10 weeks may
improve chronic prostatitis/chronic pelvis pain symptoms of
adult men [41]. Electrostimulation of Huiyin, CV2 (Qugu),
CV4, CV5 (Shimen), BL21 (Weishu), BL23 (Shenshu), BL32
(Ciliao), and auricular points of prostate and external gen-
italia also can improve LUTS in patients with transurethral
resection of the prostate [44].
The present study had some limitations: (1) the small
sample size in our trial could result in a lack of statistically
signiﬁcant diﬀerences between two groups in the IPSS and
its subscore and (2) acupuncture needles were inserted in
the subcutaneous region to a depth of 2mm in the control
group, and therefore, we could not exclude the production
of diﬀerent subliminal eﬀect [45, 46]. The adoption of a
larger sample size and diﬀerent study design might have
eliminated the two above-mentioned limitations. Although
threepatientsdevelopedecchymosis inthepresentstudy,this
ecchymosed disappeared completely, and these patients did
not withdraw form the study. We consider EA to be safe.
In conclusion, the clinical improvement of 2HzEA was
quite limited to the LUTS of patients with BPH; how to
increase the therapeutic eﬀect of EA for the LUTS treatment
of patient with BPH needs further study.
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